Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06854042 · ClinicalTrials.gov registry record · Phase 1

A Study of Oral E1018 in Healthy Adult Participants

A Phase 1 study of Healthy Participants and Malaria, sponsored by Eisai.

Recruiting
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT06854042 is a Phase 1 study of Healthy Participants and Malaria that is actively recruiting participants, run by Eisai. The registered enrollment target is 32 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06854042, a Phase 1 study of Healthy Participants and Malaria, is actively recruiting participants, sponsored by Eisai.

RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of the study is to evaluate the safety and tolerability of single ascending oral doses of E1018 in healthy adult participants and to evaluate the pharmacokinetics (PK) of E1018 in plasma and urine after single oral dose administration.

Interventions

  • DRUG Placebo
  • DRUG E1018

Study Locations (1)

Texas

  • PPD Development, LP - Austin

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-02-26
Est. Completion 2025-12-23
Phase Phase 1

Sponsor

Eisai

287 total trials

What the Registry Record Tells You About NCT06854042

The ClinicalTrials.gov registry entry for NCT06854042 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (51% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06854042 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06854042 about?

NCT06854042 is a clinical study titled "A Study of Oral E1018 in Healthy Adult Participants". The primary purpose of the study is to evaluate the safety and tolerability of single ascending oral doses of E1018 in healthy adult participants and to evaluate the pharmacokinetics (PK) of E1018 in plasma and urine after single oral dose administration.

What is the current status of trial NCT06854042?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-02-26. Estimated completion is 2025-12-23.

What conditions does trial NCT06854042 study?

This clinical trial studies the following conditions: Healthy Participants, Malaria.

What interventions are being tested in trial NCT06854042?

The interventions under investigation include: Placebo (DRUG), E1018 (DRUG).

Who is sponsoring clinical trial NCT06854042?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06854042 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.